Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Archives of Psychiatry and Clinical Neuroscience|June 12, 2002
Classifying psychotic disorders: issues regarding categorial vs. dimensional approaches and time frame to assess symptomsVictor Peralta, Manuel J Cuesta, Carlos Giraldo, et al.
Frontiers in Immunology|August 14, 2023
Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: therapeutic implications for ALSMarie-Laure Clénet, James Keaney, Gaëlle Gillet, et al.
ACM Computing Surveys|May 17, 2019
A Survey of Physics-Based Attack Detection in Cyber-Physical SystemsJairo Giraldo, David Urbina, Alvaro Cardenas, et al.
Toxicology and Applied Pharmacology|December 17, 2013
Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humansFranck A Atienzar, Eric I Novik, Helga H Gerets, et al.
NPJ Parkinson'S Disease|July 17, 2023
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's diseaseDiana L Price, Asma Khan, Rachel Angers, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 8, 2024
Deconvoluting and derisking QRS complex widening to improve cardiac safety profile of novel plasmepsin X antimalarialsAnnie Delaunois, Alvaro Cardenas, Teresa de Haro, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 8, 2024
Assessing the interplay between off-target promiscuity, cytotoxicity, and tolerability in rodents to improve the safety profile of novel anti-malarial plasmepsin X inhibitorsHelga H J Gerets, Annie Delaunois, Alvaro Cardenas, et al.
ACS Medicinal Chemistry Letters|November 17, 2023
Design of Novel Series of Antimalarial PMX Inhibitors with Increased Half-Life via Molecular Property OptimizationKomei Sakata, Martin A Lowe, Mengyang Xuan, et al.
Journal of Medicinal Chemistry|November 26, 2024
Discovery of UCB9386: A Potent, Selective, and Brain-Penetrant Nuak1 Inhibitor Suitable for In Vivo Pharmacological StudiesKarine G Poullennec, Eric Jnoff, Jan Abendroth, et al.
Nature Communications|September 5, 2018
A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug targetPrashant K Srivastava, Jonathan van Eyll, Patrice Godard, et al.
Pageof 2